Share-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Exercised	0	761,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	1.80%
Expected volatility	23.30%
Risk-free interest rate	1.30%
Expected holding period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning of period	12,107,106
Options outstanding at beginning of period, weighted average exercise price	11.63
Granted	2,036,010
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	23.00
Exercised	873,169
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	10.92
Options outstanding at end of period	13,269,947
Options outstanding at end of period, weighted average exercise price	13.41
Options exercisable at March 31, 2012	9,059,704
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	10.49
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Nonvested restricted shares at beginning of period	1,319,260
Nonvested restricted shares at beginning of period, weighted average grant date fair value	13.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	253,791
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	23.00
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(987,684)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	12.35
Nonvested restricted shares at end of period	585,367
Nonvested restricted shares at end of period, weighted average grant date fair value	19.32